

Recent volumes in the **Progress in Cancer Research and Therapy Series**

Volume 16:

Augmenting Agents in Cancer Therapy

Editors: E. M. Hersh, M. A. Chirigos, M. J. Mastrangelo

This volume reviews the current status of the use of augmenting agents to potentiate antitumor activity. Sections discuss immunotherapy with natural products and their purified subcomponents, cancer therapy with interferon inducers, therapy with synthetic polymers and other synthetic compounds, and therapy with substances such as indomethacin, cimetidine, and aziridine dyes. Approximately 585 pp., tentatively \$49.00 (November 1980) ISBN 0-89004-525-9

Volume 15:

Role of Medroxyprogesterone in Endocrine-Related Tumors

Editors: S. Iacobelli, A. DiMarco

Hormones are widely used to suppress the growth of endocrine-related tumors, particularly of the breast and endometrium. It has been hypothesized that these hormones have a direct antiproliferative effect on cancer cells and/or reduce the secretory function of endocrine tissues. This volume discusses the role of medroxyprogesterone acetate (MPA), which is important in the treatment of all endocrine-related cancers. Chapters present a rationale for hormone therapy in advanced breast and endometrial cancer, and discuss the mechanisms of action and antitumor properties of MPA. 168 pp., \$15.00 (1980) ISBN 0-89004-512-7

Volume 14:

Hormones and Cancer

Editors: S. Iacobelli, R. J. B. King, H.R. Lindner, M. E. Lippman

Recent research has revealed the importance of endocrine factors in the induction, regulation, and management of many human cancers. This volume provides a complete state-of-the-art review of this new field of endocrine oncology. Experts present basic biochemical, endocrinological, epidemiological, and animal and experimental data, as well as clinical information necessary to provide a complete understanding of the interactions between the endocrine system and neoplasia. 589 pp., \$49.00 (1980) ISBN 0-89004-486-4

Volume 13:

Colorectal Cancer: Prevention, Epidemiology, and Screening

Editors: S. J. Winawer, D. Schottenfeld, P. Sherlock

This volume focuses on the epidemiology, screening, and prevention of colorectal cancer. The first section covers the most recent insights into the interaction between epidemiology and etiology. Chapters discuss the relative roles of fiber, dietary fat, and gut flora in the mechanisms of carcinogenesis. The identification of high-risk groups is discussed in detail. Clinical and laboratory considerations are discussed in detail, as well as important issues such as patient compliance, physician awareness, and cost analysis. 432 pp., \$39.50 (1980) ISBN 0-89004-447-3

Volume 12:

Advances in Neuroblastoma Research

Editor: A. E. Evans

Human neuroblastoma as a tumor type has been a particularly useful research tool, since it thrives in culture and is thus one of the best characterized human tumor types. This volume reviews our current understanding of its growth and characteristics as a cell type and tumor. Sections are devoted to the characteristics of the disease process, genetics of the tumor, cell differentiation *in vivo* and in tissue culture, immunologic aspects, and use in the study of cytogenetics and experimental chemotherapy. Contributed chapters have been invited from a variety of fields that may provide insight into the biology of the neuroblastoma or suggest tools for its study. 360 pp., \$35.00 (1980) ISBN 0-89004-459-7

Volume 11:

Lung Cancer: Progress in Therapeutic Research

Editors: F. Muggia, M. Rozencweig

"Muggia and Rozencweig have done a good job of compiling a book that provides an overview of the current research effort in the treatment of lung cancer. . . . Essential reading for medical oncologists, thoracic surgeons, and radiation oncologists."—JAMA
639 pp., \$48.00 (1979) ISBN 0-89004-223-3

Order Form

Please send: _____

Prices subject to change without notice. Prices slightly higher outside the U.S. and Canada.

- ☐ To save postage and handling charges, I enclose payment (or charge my credit card below). N.Y. residents add 8% sales tax.
☐ Charge my credit card number: _____
Circle one: American Express VISA Diners Club
Master Charge (4-digit interbank number: _____)
Card expiration date: _____

Name (please print) _____

Address _____

Country _____ Postal Code _____

POSITION AVAILABLE

The Department of Medicine at the University of Kentucky College of Medicine is recruiting a chief for the Division of Hematology-Oncology. There are active basic science and clinical programs in cancer research within the Division and the potential for collaboration with several other departments at the Medical Center.

Interested individuals are invited to contact THEODORE A. KOTCHEN, M.D., PROFESSOR OF MEDICINE, UNIVERSITY OF KENTUCKY COLLEGE OF MEDICINE, 800 ROSE STREET, LEXINGTON, KENTUCKY 40536.

Help us to serve you better.....



**USE
YOUR
ZIP
CODE**

Remember, your zip code provides faster, more direct delivery of your journals. Use it on all correspondence, too.

*for prompt
subscription
service...*

attach label here

Please use this coupon and attach a *recent* label in the space provided when writing to us about:

- change of address
- renewal
- questions regarding your subscription

Please use the space below to indicate your *new* address.

Name of Journal _____

Name _____

Address _____

City/State/Zip _____

THE WILLIAMS & WILKINS COMPANY

428 East Preston Street/Baltimore, Maryland 21202

Director, Division of Resources, Centers, and Community Activities

The National Cancer Institute (NCI) expects to appoint a Director for the Division of Resources, Centers, and Community Activities (DRCCA). The DRCCA has been recently established as a fifth Division in the NCI. The incumbent will have primary responsibility for strengthening and reorienting NCI programs to make them more responsive to needs in the areas of prevention and transfer of research findings to the health care delivery system. The Division encompasses programs for training, education, and cancer centers which will facilitate the transfer of research findings into the health care delivery system. Specifically, the incumbent will provide program leadership and direction for the planning, developing, and coordinating of these activities with the goal of identifying, testing, evaluating, communicating, and promoting the widespread application of available and new methods for reducing the incidence, morbidity, and mortality from cancer. Additionally, the incumbent will serve as the focal point for the coordinated national effort to control cancer, and maintain liaison with other federal components and multinational elements of the private health community in the areas of prevention and transfer of research findings to the health care delivery system. The incumbent will serve as the principal advisor to the Director, NCI, the President's Cancer Panel, the National Cancer Advisory Board, and the DRCCA Board of Scientific Counselors on overall program progress.

This is a Civil Service position in the Senior Executive Service (SES) with a salary range from \$47,889 to \$50,112.50 per annum depending on qualifications. Candidates may be eligible for Physicians Comparability Pay. Alternately, candidates may be eligible for appointment in the Commissioned Corps of the U.S. Public Health Service. The SES individual selected, if not presently in the SES, must serve a one-year probationary period. Mandatory professional/technical qualifications are: a Doctor of Medicine or a Health Scientist, together with experience in the direction of a cancer research program. In addition,

candidates must meet the minimally qualified level of the mandatory managerial/executive qualifications which are: experience in the management of a cancer research program, demonstrating competence to assume leadership responsibilities in assuring that national and agency goals and priorities are considered in carrying out the functions and responsibilities of the organization; establishing and maintaining relationships with key individuals and groups outside the organization; directing and guiding programs and projects, including long-term and short-term planning, and establishing procedures for the development and defense of the organization's budget, and allocating fiscal and personnel resources to support program implementation; developing processes and overseeing activities to assure the fair and equitable employment of qualified persons, and implementing EEO objectives; and developing and implementing procedures for monitoring program performance, including periodic analysis and evaluation. Candidates who meet the mandatory requirements will be further evaluated by the Search Committee on the following factors: scientific reputation/peer recognition, training and education, honors and awards, and the degree to which they exceed the minimally qualified level of the mandatory managerial/executive qualifications. Additional information may be obtained from Ms. Jan Maltbie, Supervisory Personnel Management Specialist, NCI, (301) 496-6864. Applications (Personal Qualifications Statement, SF-171) are to be sent to the above individual at this address: National Cancer Institute, National Institutes of Health, Building 31, Room 3A27, 9000 Rockville Pike, Bethesda, MD 20205.

A current curriculum vitae, bibliography and references and/or appraisals of performance must accompany all applications. Applications of women and/or minority group members are especially solicited. The National Institutes of Health is an equal opportunity employer.

NATIONAL INSTITUTES OF HEALTH

Anti hLH Anti hCG Anti hAFP Anti hTSH

Monoclonal Antibodies...

We're Here!

Monoclonal Antibodies, Inc., announces our expanded selection of monoclonal antibodies to antigens of clinical relevance. These are suitable for immunoassays such as RIA, EIA, and immunohistochemistry, and for immune purification. Now available in two grades for research purposes: **Immunoassay Grade** and **Immunochemical Grade**.

New
Clones

- **Anti Human Chorionic Gonadotropin.** Multiple clones specific for the beta subunit (cross reactivity with LH less than 1% in some clones).

New
Clones

- **Anti Human Thyroid Stimulating Hormone.** Multiple clones specific for the beta subunit (no detectable cross reactivity with LH or hCG in some clones).

- **Anti Human Luteinizing Hormone.** Multiple clones.

- **Anti Human Alpha-Fetoprotein.**

Enter the world of **monoclonal engineering** today with these precisely defined reagents offering the homogeneity, consistency, and affinity you've wanted. Ask about our special evaluation sets. Look for additional products soon.

And we haven't forgotten:

Companion reagents especially prepared for use with monoclonals of mouse origin.

- Anti Mouse IgG
- Peroxidase Conjugated Anti Mouse IgG
- Alkaline Phosphatase Conjugated Anti Mouse IgG
- Fluorescein Conjugated Anti Mouse IgG

For further information contact:

MONOCLONAL ANTIBODIES, INC.

719 Colorado Avenue
Palo Alto, CA 94303, USA
(415) 327-2204

Not intended for human diagnostic use